EW INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Edwards Lifesciences Corporation Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

Core Viewpoint - The article discusses a class action lawsuit against Edwards Lifesciences Corporation, alleging violations of the Securities Exchange Act of 1934 by the company and its executives during a specified class period. Group 1: Lawsuit Details - The class action lawsuit is titled Patel v. Edwards Lifesciences Corporation, No. 24-cv-02221 (C.D. Cal.), and it involves purchasers of Edwards Lifesciences securities from February 6, 2024, to July 24, 2024 [1] - Investors have until December 13, 2024, to seek appointment as lead plaintiff in the lawsuit [1] - The lawsuit alleges that Edwards Lifesciences made false or misleading statements regarding its revenue outlook and growth potential, particularly concerning its Transcatheter Aortic Valve Replacement (TAVR) product [4][3] Group 2: Allegations Against the Company - The lawsuit claims that the defendants created a false impression of reliable information regarding projected revenue and growth while downplaying risks from seasonality and macroeconomic factors [4] - It is alleged that TAVR's growth was at risk of deceleration, and the company's optimistic reports did not align with actual performance, particularly in the second quarter of 2024 [4] - On July 24, 2024, Edwards Lifesciences disclosed TAVR results that fell below expectations and lowered its fiscal year 2024 projections, leading to a stock price drop of over 31% [5] Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Edwards Lifesciences securities during the class period to seek lead plaintiff status [6] - Robbins Geller Rudman & Dowd LLP is the law firm representing investors in this case, known for securing significant monetary relief for investors in securities fraud cases [7]